Published in Eur J Clin Microbiol Infect Dis on January 13, 2011
A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev (2013) 1.24
Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2012) 1.13
Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol (2011) 1.12
Vancomycin: the tale of the vanquisher and the pyrrhic victory. Perit Dial Int (2014) 0.81
Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey. BMC Infect Dis (2013) 0.81
Bloodstream infections in the Intensive Care Unit. Virulence (2016) 0.78
Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period. Front Microbiol (2016) 0.75
An Unusual Occurrence of Methicillin Resistant Staphylococcal Endocarditis with Vancomycin Creep Phenomenon - A Therapeutic Challenge. J Clin Diagn Res (2016) 0.75
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med (2006) 23.62
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis (2002) 11.30
The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 9.51
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 8.58
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 8.20
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med (2006) 7.56
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol (1998) 6.26
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother (2008) 4.21
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med (2010) 4.05
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother (2007) 3.93
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis (2007) 3.52
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol (2006) 3.34
Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis (2004) 3.13
Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis (2000) 3.02
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2004) 2.76
Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob (2006) 2.55
Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust (2001) 2.33
Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis (2006) 2.15
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol (2008) 2.07
Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents (2008) 2.03
Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother (2008) 1.51
Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother (2009) 1.47
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents (2000) 1.43
Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother (2008) 1.37
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis (2010) 1.26
High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J Clin Microbiol (2003) 1.19
Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect (2009) 1.16
Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2008) 1.08
Daptomycin in the treatment of bacteremia. Am J Med (2007) 0.91
Staphylococcus aureus bacteremia, Europe. Emerg Infect Dis (2005) 0.83
The problem with glycopeptides. Int J Antimicrob Agents (2007) 0.79
Value of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients. Infection (2014) 2.09
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Pleiotropic changes controlled by the pre-T-cell receptor. Curr Opin Immunol (1999) 1.71
Efficacy of three ethanol-based hand rubs against feline calicivirus, a surrogate virus for norovirus. J Hosp Infect (2005) 1.69
Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J (2003) 1.64
CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer (2002) 1.59
Cloning of aas, a gene encoding a Staphylococcus saprophyticus surface protein with adhesive and autolytic properties. Mol Microbiol (1998) 1.48
Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. Immunity (1997) 1.44
Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia (2003) 1.41
Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol (2013) 1.33
Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill (2011) 1.30
p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood (1997) 1.29
Comparison of phenotypic methods for penicillinase detection in Staphylococcus aureus. Clin Microbiol Infect (2008) 1.28
Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol (2004) 1.25
GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med (2009) 1.25
Fingerprints of anergic T cells. Curr Biol (2001) 1.19
Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. Immunol Rev (1998) 1.19
On the role of the pre-T cell receptor in alphabeta versus gammadelta T lineage commitment. Immunity (1998) 1.19
Inactivation of feline calicivirus, a surrogate of norovirus (formerly Norwalk-like viruses), by different types of alcohol in vitro and in vivo. J Hosp Infect (2004) 1.18
Increasing resistance against antibiotics in bacteria isolated from the lower urinary tract of an outpatient population of spinal cord injury patients. Urol Int (2004) 1.13
The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. Arthritis Rheum (2001) 1.08
Release of vancomycin and teicoplanin from a plasticized and resorbable gelatin sponge: in vitro investigation of a new antibiotic delivery system with glycopeptides. Infection (2006) 1.07
CD4+ T cell mediated intestinal immunity: chronic inflammation versus immune regulation. Gut (2005) 1.06
Sex- and strain-specific induction of renal tumors by ochratoxin A in rats correlates with DNA adduction. Int J Cancer (1998) 1.06
Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model. EMBO J (1998) 1.05
Impaired neutral sphingomyelinase activation and cutaneous barrier repair in FAN-deficient mice. EMBO J (1999) 1.04
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03
The sensitivity of direct identification from positive BacT/ALERT™ (bioMérieux) blood culture bottles by matrix-assisted laser desorption ionization time-of-flight mass spectrometry is low. Clin Microbiol Infect (2011) 1.03
Gene expression patterns of epithelial cells modulated by pathogenicity factors of Yersinia enterocolitica. Cell Microbiol (2004) 1.03
In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther (2005) 1.02
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol (1995) 1.01
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00
First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob Agents Chemother (2012) 0.99
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer (1999) 0.97
Spread of NDM-2-producing Acinetobacter baumannii in the Middle East. J Antimicrob Chemother (2013) 0.96
Evaluation of species-specific score cutoff values of routinely isolated clinically relevant bacteria using a direct smear preparation for matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based bacterial identification. Eur J Clin Microbiol Infect Dis (2011) 0.96
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer (1998) 0.95
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology (1994) 0.94
Conformational polymorphisms of cRNA of T-cell-receptor genes as a clone-specific molecular marker for cutaneous lymphoma. J Invest Dermatol (1993) 0.94
Infection of human endothelial cells with Staphylococcus aureus induces transcription of genes encoding an innate immunity response. Scand J Immunol (2005) 0.93
Virucidal activity of a new hand disinfectant with reduced ethanol content: comparison with other alcohol-based formulations. J Hosp Infect (2005) 0.92
Fatal Pseudomonas aeruginosa pneumonia in a previously healthy woman was most likely associated with a contaminated hot tub. Infection (2011) 0.92
Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. J Viral Hepat (2013) 0.92
Monitoring gene expression of TNFR family members by beta-cells during development of autoimmune diabetes. Eur J Immunol (2000) 0.90
Bilateral Bartonella henselae neuroretinitis with stellate maculopathy in a 6-year-old boy. Infection (2011) 0.90
Results and relevance of molecular detection of pathogens by SeptiFast--a retrospective analysis in 75 critically ill children. Klin Padiatr (2012) 0.90
Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation (1995) 0.89
Invasive aspergillosis in two liver transplant recipients: diagnosis by SeptiFast. Transpl Infect Dis (2009) 0.88
Inflammation in vivo is modulated by GPR83 isoform-4 but not GPR83 isoform-1 expression in regulatory T cells. Genes Immun (2010) 0.87
Comparison of virucidal activity of alcohol-based hand sanitizers versus antimicrobial hand soaps in vitro and in vivo. J Hosp Infect (2012) 0.87
Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer (2000) 0.87
[In Process Citation]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2015) 0.86
Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin Exp Immunol (1993) 0.86
Detection of hepatitis B virus DNA in serum with nucleic acid probes labelled with 32P, biotin, alkaline phosphatase or sulphone. Mol Cell Probes (1991) 0.85
FOXP3: required but not sufficient. the role of GARP (LRRC32) as a safeguard of the regulatory phenotype. Curr Mol Med (2010) 0.85
G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol (1995) 0.85
Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice. Hematol J (2001) 0.85
Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant (2005) 0.84
Evaluation of the commercially available HepProbe kit for detection of hepatitis B virus DNA in serum. J Clin Microbiol (1990) 0.84
Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia (2004) 0.84
Cytokine expression in serum and cerebrospinal fluid in non-inflammatory polyneuropathies. J Neurol Neurosurg Psychiatry (2008) 0.84
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br J Cancer (1998) 0.83
The hemagglutinin of Staphylococcus saprophyticus is a major adhesin for uroepithelial cells. Infect Immun (1996) 0.83
Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department. J Eur Acad Dermatol Venereol (2010) 0.81
Detection of small sequence differences using competitive PCR: molecular monitoring of genetically improved, mercury-reducing bacteria. Biotechniques (2001) 0.81
Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma. Br J Haematol (1997) 0.81
Performance of MicroScan WalkAway and Vitek 2 for detection of oxacillin resistance in a set of methicillin-resistant Staphylococcus aureus isolates with diverse genetic backgrounds. J Clin Microbiol (2009) 0.81
Depletion of accessory cells strongly reduces immunogenicity of T-depleted bone marrow, and thus may facilitate its engraftment. Transplant Proc (1989) 0.81
Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum Reprod (2005) 0.81
Stenotrophomonas maltophilia in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance. J Cyst Fibros (2011) 0.80
In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses (2012) 0.80
Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequence-based PCR. Med Mycol (2010) 0.80
High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia (1996) 0.80
Measurement of neutrino oscillation parameters from muon neutrino disappearance with an off-axis beam. Phys Rev Lett (2013) 0.80
Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice. Bone Marrow Transplant (2001) 0.80
Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res (2000) 0.79
[In Process Citation]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2015) 0.79
Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma. J Clin Oncol (1995) 0.79
Stabilizing properties of the halo apparatus. Spine (Phila Pa 1976) (1997) 0.79
Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol (1998) 0.79
An antithymocyte globulin of rabbit origin inhibits the antigen-induced activation of alloreactive T cells by blocking CD2. Transplant Proc (1991) 0.78
[Serum-treatment in the rubella hi-test by menas of silicic acid (author's transl)]. Zentralbl Bakteriol Orig A (1977) 0.78
Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Exp Hematol (1998) 0.78
Detection of clonal T-cell populations in gastrointestinal lymphomas by analysis of cRNA conformational polymorphisms of rearranged T-cell-receptor-gamma genes. Br J Haematol (1994) 0.78